News | February 13, 2026
IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The company’s EBITDA margin remained resilient above 20%
HCG clinicians contributing to one of the largest bodies of oncology research from India
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Subscribe To Our Newsletter & Stay Updated
